{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:51:12Z","timestamp":1791215472715,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijid.2026.108909","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:25:35Z","timestamp":1782404735000},"page":"108909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative efficacy and safety of colistin-based and alternative antibiotic regimens for multidrug-resistant Gram-negative infections: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"170","author":[{"given":"Ajaree","family":"Rayanakorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitiya","family":"Lukkunaprasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun Lee Wen","family":"Huey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7665-8819","authenticated-orcid":false,"given":"Wasan","family":"Katip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.35755\/jmedassocthai.2025.1.30-41-01303","article-title":"Outcomes and associated factors among patients with multidrug-resistant gram-negative Bacilli bacteremia at a Tertiary Care Hospital in Thailand","volume":"108","author":"Soravipukuntorn","year":"2025","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"10.1016\/j.ijid.2026.108909_bib0002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/dkq494","article-title":"Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes","volume":"66","author":"Gudiol","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.ijid.2026.108909_bib0003","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/microorganisms11071711","article-title":"Mortality due to multidrug-resistant gram-negative bacteremia in an endemic region: no better than a toss of a coin","volume":"11","author":"Tsachouridou","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/ice.2016.230","article-title":"Clinical outcomes and healthcare utilization related to multidrug-resistant gram-negative infections in community hospitals","volume":"38","author":"Dicks","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijid.2026.108909_bib0005","first-page":"1","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijid.2026.108909_bib0006","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1586\/14787210.2015.1093933","article-title":"Polymyxin B versus colistin: an update","volume":"13","author":"Cai","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"10.1016\/j.ijid.2026.108909_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","article-title":"Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?","volume":"21","author":"Ardebili","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"16","key":"10.1016\/j.ijid.2026.108909_bib0008","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ijid.2026.108909_sbref0009","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane","year":"2024"},{"issue":"11","key":"10.1016\/j.ijid.2026.108909_bib0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of Health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.ijid.2026.108909_bib0011","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1093\/cid\/ciaa121","article-title":"Clinical and Laboratory Standards Institute and European Committee on antimicrobial susceptibility testing position statements on polymyxin b and colistin clinical breakpoints","volume":"71","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108909_bib0012","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2026.108909_bib0013","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2026.108909_bib0014","series-title":"Cochrane handbook for systematic reviews of interventions: Cochrane book series","first-page":"187","article-title":"Assessing risk of bias in included studies","author":"Higgins","year":"2008"},{"key":"10.1016\/j.ijid.2026.108909_bib0015","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime Inc. Available from: https:\/\/gdt.gradepro.org\/app\/."},{"issue":"7650","key":"10.1016\/j.ijid.2026.108909_bib0016","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ijid.2026.108909_bib0017","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.ijid.2026.108909_bib0018","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s00134-017-4802-4","article-title":"Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE\u2019s STAT-Net","volume":"43","author":"Timsit","year":"2017","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.ijid.2026.108909_bib0019","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/cid\/ciac727","article-title":"Association between time to appropriate antimicrobial treatment and 30-day mortality in patients with bloodstream infections: a retrospective cohort study","volume":"76","author":"Van Heuverswyn","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ijid.2026.108909_bib0020","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz093","article-title":"Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired\/ventilator-associated bacterial pneumonia clinical trials","volume":"69","author":"Weiss","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ijid.2026.108909_bib0021","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1128\/AAC.00525-15","article-title":"Incidence, predictors, and impact on hospital mortality of amphotericin B nephrotoxicity defined using newer acute kidney injury diagnostic criteria","volume":"59","author":"Rocha","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0022","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care (Fullerton)"},{"issue":"3","key":"10.1016\/j.ijid.2026.108909_bib0023","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2026.108909_bib0024","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: application and practice using Stata","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol Health"},{"issue":"7\u20138","key":"10.1016\/j.ijid.2026.108909_bib0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.ijid.2026.108909_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijid.2026.108909_bib0027","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.ijid.2026.108909_bib0028","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.2014.8166","article-title":"Association between analytic strategy and estimates of treatment outcomes in meta-analyses","volume":"312","author":"Dechartres","year":"2014","journal-title":"JAMA: J Am Med Assoc"},{"key":"10.1016\/j.ijid.2026.108909_bib0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jgar.2018.07.003","article-title":"Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae","volume":"15","author":"Abdelsalam","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"10.1016\/j.ijid.2026.108909_bib0030","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"6","key":"10.1016\/j.ijid.2026.108909_bib0031","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0032","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.ijid.2026.108909_bib0033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0034","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"issue":"9","key":"10.1016\/j.ijid.2026.108909_bib0035","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2026.108909_bib0036","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/cer-2018-0037","article-title":"Meropenem\/colistin versus meropenem\/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia","volume":"7","author":"Khalili","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"2","key":"10.1016\/j.ijid.2026.108909_bib0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0038","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/1735-5362.363594","article-title":"The effectiveness of colistin\/levofloxacin compared to colistin\/meropenem in the treatment of ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial","volume":"18","author":"Momenzadeh","year":"2023","journal-title":"Res Pharm Sci"},{"issue":"Special Issue 2","key":"10.1016\/j.ijid.2026.108909_bib0039","first-page":"206","article-title":"Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin\/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter","volume":"17","author":"Mosaed","year":"2018","journal-title":"Iran J Pharm Res"},{"issue":"9","key":"10.1016\/j.ijid.2026.108909_bib0040","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108909_bib0041","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jgar.2018.11.016","article-title":"Colistin monotherapy versus colistin\/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial","volume":"17","author":"Park","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"10.1016\/j.ijid.2026.108909_bib0042","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2026.108909_bib0043","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijid.2026.108909_bib0044","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3390\/antibiotics11121707","article-title":"Colistin monotherapy versus colistin plus sitafloxacin for therapy of carbapenem-resistant Acinetobacter baumannii infections: a preliminary study","volume":"11","author":"Sirijatuphat","year":"2022","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.ijid.2026.108909_bib0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/antibiotics13020137","volume":"13","author":"Wantanatavatod","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijid.2026.108909_bib0046","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1016\/j.csbj.2024.05.043","article-title":"Transcriptomic investigations of polymyxins and colistin\/sulbactam combination against carbapenem-resistant Acinetobacter baumannii","volume":"23","author":"Bian","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"10.1016\/j.ijid.2026.108909_bib0047","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jmii.2024.01.009","article-title":"Comparison of in vitro synergy between polymyxin B or colistin in combination with 16 antimicrobial agents against multidrug-resistant Acinetobacter baumannii isolates","volume":"57","author":"Wang","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.ijid.2026.108909_bib0048","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01258-23","article-title":"In vitro activity of sulbactam-durlobactam against colistin-resistant and\/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals","volume":"68","author":"Iovleva","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijid.2026.108909_bib0049","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11592900-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2026.108909_bib0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vascn.2015.11.007","article-title":"Penetration of antimicrobials to pulmonary epithelial lining fluid and muscle and impact of drug physicochemical properties determined by microdialysis","volume":"78","author":"Rottb\u00f8ll","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"3","key":"10.1016\/j.ijid.2026.108909_bib0051","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3947\/ic.2018.50.3.283","article-title":"Exploring new predictors of colistin-associated nephrotoxicity","volume":"50","author":"Kim","year":"2018","journal-title":"Infect Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0052","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antibiotics8010024","article-title":"Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity","volume":"8","author":"Nation","year":"2019","journal-title":"Antibiotics"},{"issue":"12","key":"10.1016\/j.ijid.2026.108909_bib0053","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase\u2013producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0054","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care (Fullerton)"},{"key":"10.1016\/j.ijid.2026.108909_bib0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0056","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13756-021-00931-w","article-title":"Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture","volume":"10","author":"Iskandar","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"10.1016\/j.ijid.2026.108909_bib0057","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/S2666-5247(22)00387-1","article-title":"International manufacturing and trade in colistin, its implications in colistin resistance and One Health global policies: a microbiological, economic, and anthropological study","volume":"4","author":"Umair","year":"2023","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.ijid.2026.108909_bib0058","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226005448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226005448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:54:24Z","timestamp":1791212064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226005448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"alternative-id":["S1201971226005448"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108909","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of colistin-based and alternative antibiotic regimens for multidrug-resistant Gram-negative infections: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108909"}}